Xolair 150mg-SW (Omalizumab Vials) 150mg

Xolair 150mg-SW (Omalizumab) is an injectable prescription medication used for allergic asthma and chronic urticaria. Store between 2-8°C to maintain potency. Always follow healthcare provider guidance for safe use.

Strength

150mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Novartis Pharma Schweiz AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Xolair 150mg-SW (Omalizumab) is used to treat moderate to severe persistent allergic asthma in adults and adolescents. It is also prescribed for chronic spontaneous urticaria in patients who remain symptomatic despite antihistamine treatment. This medication helps reduce asthma attacks and hives by targeting specific immune responses.

Side Effects

Xolair 150mg-SW (Omalizumab) works by binding to immunoglobulin E (IgE) in the body, which can help reduce allergy symptoms over time. Patients may notice fewer asthma flare-ups or hives with regular use. Individual responses vary, and consistent use is important for best results.

Precautions & Warnings

Keep Xolair 150mg-SW (Omalizumab) refrigerated between 2-8°C and protect from light. Do not freeze or shake vigorously. Always check the vial for particles or discoloration before use. Discard any unused medication as directed by your healthcare provider.

Avoid Interactions

Xolair 150mg-SW (Omalizumab) has a low risk of drug interactions, but inform your doctor about all medications you take. No specific interactions with alcohol or common over-the-counter drugs have been widely reported. Always consult your healthcare provider before combining therapies.

Frequently Asked Questions

Xolair 150mg-SW is used to treat moderate to severe allergic asthma and chronic spontaneous urticaria in patients who do not respond adequately to other treatments.

Xolair 150mg-SW is given as an injection under the skin (subcutaneous) by a healthcare professional, typically every 2 to 4 weeks.

No, Xolair 150mg-SW must be stored refrigerated between 2-8°C and protected from light to maintain its effectiveness.

Common side effects may include injection site reactions, headache, or fatigue. Severe allergic reactions are rare but possible.

Xolair 150mg-SW is approved for adolescents aged 12 and older with allergic asthma and adults with chronic urticaria.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.